by Madaline Spencer | Dec 4, 2025
Richard Lafayette, MD, Professor of Medicine at Stanford University, discusses the ORIGIN clinical trial evaluating atacicept in adults with IgA nephropathy (IgAN). IgAN is a kidney disorder that occurs when IgA (immunoglobulin A) protein settles in the...
by Madaline Spencer | Dec 3, 2025
The U.S. Food and Drug Administration (FDA) has approved Hyrnua (sevabertinib) for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain activating mutations. NSCLC with HER2...
by Madaline Spencer | Dec 3, 2025
Jonathan Strober, MD, pediatric neurologist and neuromuscular specialist at the University of California at San Francisco, discusses the use of nipocalimab in adolescent patients with generalized myasthenia gravis (gMG). gMG is a chronic autoimmune...
by Madaline Spencer | Dec 2, 2025
Michael A. Levine, MD, ML, Children’s Hospital of Philadelphia, discusses positive topline results from the CALIBRATE trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare form of hypoparathyroidism caused by...
by Madaline Spencer | Dec 1, 2025
Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with generalized myasthenia gravis (gMG). gMG is a chronic...
